CellScope Raises $1M From Khosla Ventures

[Techtaffy Newsdesk]

CellScope, a mobile health startup building systems for at-home diagnosis, and recent graduate of Rock Health’s first class of startups, has raised $1million in seed funding from Khosla Ventures.

The company’s first product is a smartphone-enabled otoscope for remote diagnosis of pediatric ear infections, which cause 30 million doctor visits annually in the US. Parents will be able to use the device to share images of the eardrum with remote pediatricians for diagnosis, treatment and monitoring.

Vinod Khosla: Health data, the key ingredient to useful analysis and diagnosis, is starting to explode exponentially.

CellScope started in bioengineering Professor Dan Fletcher’s lab at UC Berkeley working on mobile microscopy for remote diagnosis in developing countries. The team went through Rock Health’s first class in San Francisco in 2011. Future CellScope products will leverage the platform for throat and skin exams and non-clinical applications including consumer skincare, says the company. The system is currently in pilot testing with doctors in the Bay Area.

[Image Courtesy: Cellscope]

Just in

A comprehensive list of 2023 & 2024 tech layoffs — TC

The final total of layoffs for 2023 ended up being 262,735, according to Tech layoffs conducted in 2023 were 59% higher than 2022’s total.

Gradial raises $5.4M

Gradial, based in Seattle, WA, has announced a $5.4 million seed funding round. The investment is led by Madrona.

CMS awards ICF $50M in digital modernization contract extensions

The U.S. Department of Health and Human Services (HHS) has extended two contracts with ICF for the cloud migration and digital modernization of Centers for Medicare & Medicaid (CMS) systems.

Court orders maker of Pegasus spyware to hand over code to WhatsApp — The Guardian

NSO Group, the maker of one the world’s most sophisticated cyber weapons, has been ordered by a US court to hand its code for Pegasus and other spyware products to WhatsApp as part of the company’s ongoing litigation, writes Stephanie Kirchgaessner.